@EASLnews @EASLedu PGC: Prof. Hezode highlights one of the last frontier of #HCV therapy: the compensated, cirrhotic GT3, rx experienced patient. #Vosevi 12 weeks or #mavyret 16 weeks increases the cure rate to high 90% #ilc2018
No additional benefit of #vosevi over #epclusa among #HCV GT1b,2,4,5,6 who failed #sovaldi so remains a rare unmet need
#Vosevi for #HCV treatment contraindicated with rifampin and decompensated cirrhosis. Not recommended with cyclosporine
Somewhat surprisingly #Vosevi approved only for DAA non responders
